- Home
- EVAC vs PHAT Comparison
EVAC vs PHAT Comparison
Compare EVAC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAC | PHAT |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.7M | 590.6M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVAC | PHAT |
|---|---|---|
| Price | $10.32 | $7.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $20.45 |
| AVG Volume (30 Days) | 189.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $80.58 |
| Revenue Next Year | N/A | $56.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $9.94 | $6.52 |
| 52 Week High | $10.33 | $18.31 |
Technical Indicators
Market Signals| Indicator | EVAC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 42.53 |
| Support Level | $10.25 | $6.91 |
| Resistance Level | N/A | $9.74 |
| Average True Range (ATR) | 0.01 | 0.36 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 75.00 | 56.06 |
Price Performance
Historical ComparisonAbout EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.